Coagil-VII®

Recombinant activated coagulation factor VII, which is required for the treatment of inhibitor form of haemophilia. It is also used during surgical interventions in patients with inhibitor form of haemophilia or Glanzmann thrombasthenia. Coagil-VII is a universal hemostatic agent; its successful application was reported in cases of major hemorrhage not related to hemophilia, including liver failure, major surgery, multiple trauma, postpartum bleeding, etc.

Coagil-VII was launched onto the Russian market in 2009. Also approved in Kazakhstan, Azerbaijan, Uzbekistan.

GENERIUM is the only company in the world, which manufactures three recombinant coagulation factors (FVII, FVII and FIX) for the treatment of hemophilia A and B, including its inhibitor form.